[go: up one dir, main page]

CA2278739A1 - Thiazole benzenesulfonamides utilises comme agonistes .beta.3 pour le traitement du diabete et de l'obesite - Google Patents

Thiazole benzenesulfonamides utilises comme agonistes .beta.3 pour le traitement du diabete et de l'obesite Download PDF

Info

Publication number
CA2278739A1
CA2278739A1 CA002278739A CA2278739A CA2278739A1 CA 2278739 A1 CA2278739 A1 CA 2278739A1 CA 002278739 A CA002278739 A CA 002278739A CA 2278739 A CA2278739 A CA 2278739A CA 2278739 A1 CA2278739 A1 CA 2278739A1
Authority
CA
Canada
Prior art keywords
ethyl
phenyl
hydroxy
benzenesulfonamide
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002278739A
Other languages
English (en)
Inventor
Emma R. Parmee
Robert J. Mathvink
Ann E. Weber
Samuel Tolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705041.3A external-priority patent/GB9705041D0/en
Application filed by Individual filed Critical Individual
Publication of CA2278739A1 publication Critical patent/CA2278739A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Les benzènesulfonamides à substitution thiazole sont des agonistes du récepteur adrénergique .beta.¿3? présentant une très faible activité de récepteur adrénergique .beta.¿1? et .beta.¿2?, et en tant que tels, ces composés peuvent accroître la lipolyse et la dépense énergétique dans les cellules. Ces composés sont par conséquent très efficaces dans le traitement du diabète de type II et de l'obésité. Ces composés peuvent également être utilisés pour abaisser les taux de triglycéride et de cholestérol ou augmenter les taux de lipoprotéine haute densité ou diminuer le transit intestinal. En outre, ces composés peuvent être utilisés pour réduire l'inflammation neurogène ou comme antidépresseurs. Ces composés sont préparés par couplage d'un aminoalkylphénylsulfonamide avec un époxyde substitué de façon approprié. L'invention concerne également des composés et des méthodes pour utiliser les composés dans le traitement du diabète et de l'obésité et pour abaisser les taux de triglycéride et de cholestérol ou augmenter les taux de lipoprotéine haute densité ou diminuer le transit intestinal.
CA002278739A 1997-01-28 1998-01-23 Thiazole benzenesulfonamides utilises comme agonistes .beta.3 pour le traitement du diabete et de l'obesite Abandoned CA2278739A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3676097P 1997-01-28 1997-01-28
US60/036,760 1997-01-28
GB9705041.3 1997-03-12
GBGB9705041.3A GB9705041D0 (en) 1997-03-12 1997-03-12 Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity
PCT/US1998/001317 WO1998032753A1 (fr) 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES UTILISES COMME AGONISTES β3 POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE

Publications (1)

Publication Number Publication Date
CA2278739A1 true CA2278739A1 (fr) 1998-07-30

Family

ID=26311166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002278739A Abandoned CA2278739A1 (fr) 1997-01-28 1998-01-23 Thiazole benzenesulfonamides utilises comme agonistes .beta.3 pour le traitement du diabete et de l'obesite

Country Status (22)

Country Link
EP (1) EP0968209A1 (fr)
JP (1) JP2001509166A (fr)
KR (1) KR20000070568A (fr)
CN (1) CN1251099A (fr)
AR (1) AR011092A1 (fr)
AU (1) AU728812B2 (fr)
BG (1) BG103686A (fr)
BR (1) BR9807096A (fr)
CA (1) CA2278739A1 (fr)
EA (1) EA199900692A1 (fr)
EE (1) EE9900328A (fr)
HR (1) HRP980044A2 (fr)
HU (1) HUP0002053A3 (fr)
ID (1) ID22273A (fr)
IL (1) IL131130A0 (fr)
IS (1) IS5131A (fr)
NO (1) NO993646L (fr)
PE (1) PE52299A1 (fr)
PL (1) PL334833A1 (fr)
SK (1) SK100099A3 (fr)
TR (1) TR199902442T2 (fr)
WO (1) WO1998032753A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
CA2397554C (fr) 2000-01-21 2009-09-22 Novartis Ag Combinaisons comprenant des inhibiteurs de la dipeptidylpeptidase- iv et des agents antidiabetiques
EP1258253A1 (fr) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Nouveaux remedes et utilisation d'un agoniste beta3
EP1138685B1 (fr) 2000-03-31 2004-05-19 Pfizer Products Inc. Procédé de préparation de pyridines substituées
PL360098A1 (en) * 2000-07-13 2004-09-06 Eli Lilly And Company Beta3 adrenergic agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
CA2421594A1 (fr) 2000-11-10 2002-05-16 John Arnold Werner Agonistes du recepteur beta-3 d'oxindole 3-substitue
DE60139639D1 (de) * 2000-12-08 2009-10-01 Takeda Pharmaceutical Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
EP1404672B1 (fr) * 2001-06-22 2006-01-18 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
EP1421078B1 (fr) 2001-08-14 2006-09-27 Eli Lilly And Company Derives d'indole en tantqu'agonistes du recepteur beta-3 adrenergique pour le traitement du diabete type 2
ES2262817T3 (es) 2001-08-14 2006-12-01 Eli Lilly And Company Agonistas beta-3 oxindol 3-sustituidos.
DE60208815T2 (de) * 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit
WO2003044016A1 (fr) 2001-11-20 2003-05-30 Eli Lilly And Company Agonistes $g(b)3 a base d'oxindole 3-substitue
AU2002353844A1 (en) 2001-11-20 2003-06-10 Eli Lilly And Company Beta 3 adrenergic agonists
EP1467733A1 (fr) 2002-01-11 2004-10-20 Eli Lilly And Company Derives d'ethanolamine a substitution de 2-oxo-benzimidazolyle, et leur utilisation comme beta3 agonistes
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (fr) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
WO2006132196A1 (fr) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation PRODUIT PHARMACEUTIQUE ORIGINAL COMPRENANT UN AGONISTE β3
CN102908350B (zh) 2005-09-14 2014-07-23 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP1937264B1 (fr) 2005-10-04 2011-06-08 Merck Sharp & Dohme Corp. Polytherapie destinee au traitement de la pollakiurie, de la miction imperieuse et de l'incontinence urinaire
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
CA2682727C (fr) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Derive d'indoledione
CA2688161C (fr) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (fr) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Nouveaux derives d'azabenzimidazole cyclique utiles en tant qu'agents antidiabetiques
BR112015002080A2 (pt) 2012-08-02 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (fr) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (fr) * 1982-04-08 1984-12-05 Beecham Group Plc Dérivés de l'éthanolamine, procédé pour leur préparation et compositions pharmaceutiques les contenant
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO1998032753A1 (fr) 1998-07-30
IL131130A0 (en) 2001-01-28
AU728812B2 (en) 2001-01-18
ID22273A (id) 1999-09-23
NO993646D0 (no) 1999-07-27
KR20000070568A (ko) 2000-11-25
EE9900328A (et) 2000-02-15
BR9807096A (pt) 2000-04-18
AU6038498A (en) 1998-08-18
PL334833A1 (en) 2000-03-27
TR199902442T2 (xx) 2000-07-21
EA199900692A1 (ru) 2000-02-28
AR011092A1 (es) 2000-08-02
IS5131A (is) 1999-07-23
BG103686A (bg) 2000-06-30
CN1251099A (zh) 2000-04-19
SK100099A3 (en) 2000-05-16
JP2001509166A (ja) 2001-07-10
EP0968209A1 (fr) 2000-01-05
HRP980044A2 (en) 1998-10-31
PE52299A1 (es) 1999-05-26
HUP0002053A2 (hu) 2001-08-28
HUP0002053A3 (en) 2001-09-28
NO993646L (no) 1999-09-27

Similar Documents

Publication Publication Date Title
AU728812B2 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
AU712057B2 (en) Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
US6011048A (en) Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
US6291491B1 (en) Amide derivatives as β 3 agonists
JP3149186B2 (ja) 糖尿病および肥満の治療のための選択的β▲下３▼作用物質としての置換スルホンアミド
AU717699B2 (en) Chemical compounds
US5451677A (en) Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
JP5290749B2 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
US5705515A (en) Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
US5716967A (en) Isoxazoline compounds as antiinflammatory agents
RU2501794C2 (ru) Активирующий агент для рецептора, активируемого стимулирующими рост пероксисом агентами
NZ328900A (en) Substituted phenyl or pyridyl substituted phenyl, benzo[b]furan or indolyl derivatives and medicaments
JPWO2002046176A1 (ja) ペルオキシソーム増殖剤応答性受容体の活性化剤
JPH01143856A (ja) 抗アレルギーおよび抗炎症剤用２−アリール置換複素環式化合物
US20100087446A1 (en) 2-substituted indole derivatives as calcium channel blockers
JPWO2004087641A1 (ja) ヒドラゾン誘導体
JP4986927B2 (ja) 医薬
US6034106A (en) Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
EP0767782B1 (fr) Derives d'aryle et heteroaryle alkoxynaphtalene
CZ268199A3 (cs) Thiazolbenzensulfonamidy a farmaceutický prostředek
MXPA99007032A (en) THIAZOLE BENZENESULFONAMIDES AS&bgr;3
JP2019520400A (ja) 新規シクロプロピル誘導体
GB2356196A (en) Guanidine and ethylenediamine derivatives as beta 3 agonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued